Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.70
-0.4400-0.40%
Volume:41.36K
Turnover:4.57M
Market Cap:1.01B
PE:89.70
High:111.04
Open:111.04
Low:110.01
Close:111.14
52wk High:118.00
52wk Low:85.91
Shares:9.09M
Float Shares:9.09M
Volume Ratio:0.39
T/O Rate:0.46%
Dividend:2.18
Dividend Rate:1.97%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):142.57

Loading ...

Lilly Says Foundayo Has Captured over 30% of New US Patients on Oral Weight-Loss Drugs

Reuters
·
Yesterday

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

NYSE Order Imbalance 99880.0 Shares on Sell Side

THOMSON REUTERS
·
Yesterday

Merck & Co Exec Says Potential 340B and Policy Evolutions Would Create Tailwinds but are not Material to the Business - Morgan Stanley Conf

THOMSON REUTERS
·
Yesterday

Merck & Co Exec Says Timing for Raising the $70 Bln Forecast is "to be Determined" Adds "It's Coming"

THOMSON REUTERS
·
Yesterday

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Yesterday

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Yesterday

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Yesterday

Novartis AG Rises Monday, Outperforms Market

Dow Jones
·
Yesterday

Novo Nordisk A/S Series B Stock Rises Monday, Outperforms Market

Dow Jones
·
Yesterday

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

TIPRANKS
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Data Retention Terms Prompt Restraints on AI Model Use for Sensitive Operations

Deep News
·
Sep 14

Novo Signals New Direction of Travel with Rebrand

Dow Jones
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Sep 14